Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

TAVR: Medtronic's big milestone | 11% of sites deliver below-average care | Permanent pacemakers & valve-in-valve TAVR

News You Need to Know Today
TAVR: Medtronic's big milestone | 11% of sites deliver below-average care | Permanent pacemakers & valve-in-valve TAVR
Thursday, May 20, 2021
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Editor's Choice: TAVR

Apixaban appears safe for most TAVR patients, but questions remain

Researchers tracked data from more than 1,500 patients who underwent a successful TAVR procedure from 2016 to 2019. 

READ MORE >
elderly patient mask covid
Share on Twitter Share on Facebook Share on Linkedin

Apixaban appears safe for most TAVR patients, but questions remain

Share on Twitter Share on Facebook Share on Linkedin
elderly patient mask covid
Researchers tracked data from more than 1,500 patients who underwent a successful TAVR procedure from 2016 to 2019. 
READ MORE >

A milestone for Medtronic: Low-risk TAVR patients treated with Evolut ‘doing exceptionally well’ after 2 years

The two-year rates of all-cause mortality or disabling stroke were 4.3% for TAVR patients and 6.3% for SAVR patients.

READ MORE >
Large peridevice leaks after left atrial appendage occlusion (LAAO) are incredibly rare and not associated with a greater risk of adverse outcomes, according to new research published in JACC: Clinical Electrophysiology.[1] Smaller residual links are more common, however, and associated with a risk of thromboembolic and bleeding events.
Share on Twitter Share on Facebook Share on Linkedin

A milestone for Medtronic: Low-risk TAVR patients treated with Evolut ‘doing exceptionally well’ after 2 years

Share on Twitter Share on Facebook Share on Linkedin
Large peridevice leaks after left atrial appendage occlusion (LAAO) are incredibly rare and not associated with a greater risk of adverse outcomes, according to new research published in JACC: Clinical Electrophysiology.[1] Smaller residual links are more common, however, and associated with a risk of thromboembolic and bleeding events.
The two-year rates of all-cause mortality or disabling stroke were 4.3% for TAVR patients and 6.3% for SAVR patients.
READ MORE >

BASILICA before TAVR is safe and effective, new data confirms

Researchers found that the procedure was associated with a high success rate and low mortality and stroke rates after 30 days.

READ MORE >
Same-day discharge after TAVR is safe for low-risk patients, leads to considerable cost savings
Share on Twitter Share on Facebook Share on Linkedin

BASILICA before TAVR is safe and effective, new data confirms

Share on Twitter Share on Facebook Share on Linkedin
Same-day discharge after TAVR is safe for low-risk patients, leads to considerable cost savings
Researchers found that the procedure was associated with a high success rate and low mortality and stroke rates after 30 days.
READ MORE >

Abbott’s new self-expanding TAVR system gains CE mark approval

The solution has still only been approved in the United States for investigational use. 

READ MORE >
approved approval
Share on Twitter Share on Facebook Share on Linkedin

Abbott’s new self-expanding TAVR system gains CE mark approval

Share on Twitter Share on Facebook Share on Linkedin
approved approval
The solution has still only been approved in the United States for investigational use. 
READ MORE >

AI model helps clinicians predict post-TAVR infective endocarditis

To build and validate their advanced AI model, researchers explored data from nearly 78,000 TAVR hospitalizations.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

AI model helps clinicians predict post-TAVR infective endocarditis

Share on Twitter Share on Facebook Share on Linkedin
To build and validate their advanced AI model, researchers explored data from nearly 78,000 TAVR hospitalizations.
READ MORE >

11% of TAVR sites deliver below-average care, suggesting a ‘meaningful performance gap’

The study’s authors developed and validated a new performance measure for TAVR care using data from more than 52,000 patients. They shared their full analysis ahead of print in Circulation.

READ MORE >
quality imaging appropriateness clinical decision support CAS AUC
Share on Twitter Share on Facebook Share on Linkedin

11% of TAVR sites deliver below-average care, suggesting a ‘meaningful performance gap’

Share on Twitter Share on Facebook Share on Linkedin
quality imaging appropriateness clinical decision support CAS AUC
The study’s authors developed and validated a new performance measure for TAVR care using data from more than 52,000 patients. They shared their full analysis ahead of print in Circulation.
READ MORE >

1 in 10 patients with post-TAVR infective endocarditis have a stroke, increasing risk of death by 90%

When patients with post-TAVR infective endocarditis have a stroke, their risk of in-hospital mortality and all-cause mortality after one year both skyrocket. 

READ MORE >
HF-related mortality among older adults improved from 1999 to 2012, but then decreased considerably over the next several years. Researchers explored the latest data at length, sharing their findings in JACC: Heart Failure.
Share on Twitter Share on Facebook Share on Linkedin

1 in 10 patients with post-TAVR infective endocarditis have a stroke, increasing risk of death by 90%

Share on Twitter Share on Facebook Share on Linkedin
HF-related mortality among older adults improved from 1999 to 2012, but then decreased considerably over the next several years. Researchers explored the latest data at length, sharing their findings in JACC: Heart Failure.
When patients with post-TAVR infective endocarditis have a stroke, their risk of in-hospital mortality and all-cause mortality after one year both skyrocket. 
READ MORE >

How valve type and anesthesia strategy affect 1-year TAVR outcomes

Researchers in Germany explored data from more than 400 TAVR patients, sharing their findings in the Journal of the American College of Cardiology. 

READ MORE >
Patient
Share on Twitter Share on Facebook Share on Linkedin

How valve type and anesthesia strategy affect 1-year TAVR outcomes

Share on Twitter Share on Facebook Share on Linkedin
Patient
Researchers in Germany explored data from more than 400 TAVR patients, sharing their findings in the Journal of the American College of Cardiology. 
READ MORE >

Risk of a permanent pacemaker after valve-in-valve TAVR is low, especially when using newer heart valves

The findings, published in the Journal of the American College of Cardiology, focused on data from the VIVID registry.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Risk of a permanent pacemaker after valve-in-valve TAVR is low, especially when using newer heart valves

Share on Twitter Share on Facebook Share on Linkedin
The findings, published in the Journal of the American College of Cardiology, focused on data from the VIVID registry.
READ MORE >

SCAI 2021: Medtronic pleased with 30-day data on Evolut TAVR systems

Researchers presented 30-day data at the SCAI 2021 Scientific Sessions, highlighting the "excellent" outcomes and the importance of constantly working to improve patient care. 

READ MORE >
Cardiologist heart
Share on Twitter Share on Facebook Share on Linkedin

SCAI 2021: Medtronic pleased with 30-day data on Evolut TAVR systems

Share on Twitter Share on Facebook Share on Linkedin
Cardiologist heart
Researchers presented 30-day data at the SCAI 2021 Scientific Sessions, highlighting the "excellent" outcomes and the importance of constantly working to improve patient care. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Physicians push back after government report | Device recalled | A lesson for PAD patients | AI for long-term stroke risk
The pros & cons of direct-to-patient drug programs | Why PAD patients should listen to their doctors
Coffee linked to major heart risk | Ablations in ASCs | Catheters recalled | A closer look at PFA | GLP-1 drugs & AFib
New guidelines for cardiovascular-kidney-metabolic syndrome and M-TEER | HF cell therapy company raises $4.4 million
Cardiac robotic surgery on patient 12,500 miles away | $13M for Star Trek actor HF malpractice case | New leadless pacemaker
Supreme Court sides supports cardiac drug maker | X-ray assesses pulmonary valve regurgitation | Making cardiac data actionable
Week in Review: Former ACC president dies | Administration questions vascular care | Is coffee bad for the heart | FFR-CT guide

Pagination

    • First page « First
    • Previous page ‹‹
    • Page 1
    • Current page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme